Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia-Reference-Cited by-同舟云学术

Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia

Published:2015-10 Issue: Volume:606 Page:7-12
ISSN:0304-3940
Container-title:Neuroscience Letters
language:en
Short-container-title:Neuroscience Letters

Author:

Strzelecki Dominik^ORCID,Podgórski Michał^ORCID,Kałużyńska Olga,Gawlik-Kotelnicka Oliwia,Stefańczyk Ludomir,Kotlicka-Antczak Magdalena^ORCID,Gmitrowicz Agnieszka,Grzelak Piotr

Funder

Polish Ministry of Science and Higher Education

Publisher

Elsevier BV

Subject

General Neuroscience

Reference58 articles.

1. Schizophrenia: a concise overview of incidence, prevalence, and mortality;McGrath;Epidemiol. Rev.,2008

2. A systematic review and meta-analysis of recovery in schizophrenia;Jääskeläinen;Schizophr. Bull.,2013

3. Network interactions in schizophrenia –therapeutic implications;Carlsson;Brain Res. Brain Res. Rev.,2000

4. The glutamatergic dysfunction hypothesis for schizophrenia;Coyle;Harv. Rev. Psychiatry,1996

5. NMDA receptor hypofunction model of schizophrenia;Olney;J. Psychiatr. Res.,1999

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress on polySarcosine as an alternative to PEGylation: Synthesis and biomedical applications;International Journal of Pharmaceutics;2024-03

2. Editorial: Glutamatergic system in affective and psychotic disorders: pre-clinical and clinical advances;Frontiers in Neuroscience;2024-01-09

3. Sarcosine May Induce EGF Production or Inhibit the Decline in EGF Concentrations in Patients with Chronic Schizophrenia (Results of the PULSAR Study);Pharmaceuticals;2023-11-03

4. Update on Oxytocin, Phosphodiesterase, Neurokinin, Glycine as a Therapeutic Approach in the Treatment of Schizophrenia;CNS & Neurological Disorders - Drug Targets;2023-08

5. Influence of glutamatergic and GABAergic neurotransmission on obstructive sleep apnea;Frontiers in Neuroscience;2023-07-13